BioProspect (BPO) is developing a new paradigm in
psychiatric diagnosis based on Heart Rate Variability (HRV) technology that
utilises human heart rate characteristics, including certain tell-tale changes,
as sensitive measures for depression. The HRV technology consists of a
heart monitor that sends recordings wirelessly to the internet where a
proprietary algorithm analyses and delivers a quantifiable score for depressive
illness.
This innovative technology is non-intrusive, quick, objective, decisive and will revolutionise the diagnosis and treatment of mental health.
The HRV Technology is the first objective, evidence based approach to
the diagnosis of depression and other affective disorders.
Depression is estimated to cost AUS $15 billion annually.
